EURRUS Biotech GmbH ("Eurrus") is incorporated in Tulln, Austria. Founded in 2006 the existing partners joined in 2012. Development focus is Asthma with a newly developed API. Development status has reached CP IIb.
R&D:Medical indication: Eosinophilic Asthma Bronchial EURRUS BIOTECH GMBH is granted a worldwide and unlimited development and exploitation patent license from Pharmenterprise LLC for XC-8 including patent utilization/sale with the exception of Russia and CIS. The target for this project is the clinical development up to Phase IIb and outlicencing to strategic partners in 2021/2022. CP IIb is expected to be finished in 2021.